Topics
Metastases to the CNS | Treatment | Clinical trials | Non-small cell lung cancer
Home > Publications > Topics > Metastases to the CNS > Treatment > Clinical trials > Non-small cell lung cancer
Mehta MP, Gondi V, Ahluwalia MS, Roberge D, Sio TTW, Trifiletti
DM, Muanza T, Krpan AM, Zhu Z, Ramakrishna NR, Fiveash JB,
Metellus P, Yu J, Wang CJ, Jacob J, Freyschlag CF, Csőszi T,
Salmaggi A, Taliansky A, Lucas A, Debus J, Brown PD, Harat M;
METIS study investigators.
Tumor
Treating Fields (TTFields) therapy after stereotactic radiosurgery
for brain metastases from non-small cell lung cancer: final
results of the phase 3 METIS study.
Int
J Radiat Oncol Biol Phys. 2025 Sep
29:S0360-3016(25)06217-0. doi:
10.1016/j.ijrobp.2025.08.066. PMID:
41033612. Interventional study. ˍ
Fuereder T, Garde-Noguera J, García-Mosquera JJ,
Ruiz-Borrego M, Valero M, Llombart-Cussac A, Gion M, Greil R,
Arumi M, Campolier M, Guerrero JA, Raimondi G, Mancino M,
Jiménez-Cortegana C, Vaz-Batista M, Oberndorfer F, Marhold
M, Berghoff AS, Furtner J, Bartsch R, Preusser M.
Patritumab
deruxtecan (HER3-DXd) in patients with active brain metastases of
non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm,
phase 2 trial.
Lancet
Oncol. 2025 Oct 27;26(11):1454-1466. doi:
10.1016/S1470-2045(25)00465-6. PMID:
41167214. Interventional
study˰
ˍ